SCHEDULE: Bank of America Reports Stake in Jasper Therapeutics

Bank of America Corp /DE/ has reported beneficial ownership of 6.4% of Jasper Therapeutics, Inc. common stock as of September 30, 2026.

Summary

• Bank of America Corp /DE/ has filed a Schedule 13G, indicating it beneficially owns 2,133,861 shares of Jasper Therapeutics, Inc. common stock.
• This represents 6.4% of the class of securities outstanding.
• The filing is made on behalf of Bank of America Corp /DE/ and its wholly owned subsidiaries, including BofA Securities, Inc., Bank of America N.A., and Merrill Lynch International.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting a change in beneficial ownership without significant new financial or strategic information.

Positives

• Bank of America's investment indicates confidence or market-making activity in Jasper Therapeutics.
• The filing clearly states the ownership percentage and number of shares, providing transparency.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Jasper Therapeutics.
• The nature of Bank of America's ownership (e.g., investment, market-making) is not detailed beyond 'ordinary course of business'.

Risks

• The filing does not explicitly mention any new risks for Jasper Therapeutics.
• Potential risks for investors could stem from the lack of detailed information regarding the purpose of Bank of America's stake.

Future Outlook

The filing does not contain any forward-looking statements or guidance regarding Jasper Therapeutics' future performance or Bank of America's future stake.

Management Comments

• "The beneficial ownership calculation relies on the 33,274,561 outstanding shares disclosed in the Form DEFA14A by the issuer on October 19, 2026, which reports share totals as of September 28, 2026."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive ownership by institutional investors or entities acting as market makers. This filing suggests Bank of America has taken a significant, but likely non-controlling, position in Jasper Therapeutics, which could be for investment or client-related services.

Stakeholder Impact

• Shareholders of Jasper Therapeutics, Inc.: The filing provides transparency on a significant institutional holder, which may influence market perception.
• Bank of America Corp /DE/: The filing confirms its holdings and compliance with regulatory requirements.

Next Steps

• Bank of America will continue to hold its shares in Jasper Therapeutics, Inc. in the ordinary course of business.
• Jasper Therapeutics, Inc. will continue its operations as disclosed in its other filings.

Key Dates

Keywords

beneficial ownership, Schedule 13G, Bank of America, Jasper Therapeutics, common stock, investment, Delaware